DSS, Inc. Reports Strong Q1 2025 Financial Performance, Setting the Stage for Strategic Growth
DSS reported strong Q1 2025 financial results, demonstrating significant progress in its financial repositioning strategy. The company achieved 28% year-over-year revenue growth, driven by a 30% increase in printed product sales and an impressive 78.5% growth in rental income from $400,000 to $714,000. Key financial highlights include the successful sale of its Plano, TX facility for $9.5 million, debt reduction of over $8 million, and a $1.5 million equity capital raise through Impact BioMedical. Operating cash flow improved, with net cash used in operations decreasing from $2.15 million in Q1 2024 to $1.64 million in Q1 2025.
DSS ha riportato solidi risultati finanziari nel primo trimestre 2025, dimostrando notevoli progressi nella sua strategia di riposizionamento finanziario. L'azienda ha registrato una crescita dei ricavi del 28% su base annua, trainata da un aumento del 30% nelle vendite di prodotti stampati e da una crescita impressionante del 78,5% nei ricavi da noleggio, passati da 400.000 a 714.000 dollari. Tra i principali risultati finanziari si segnalano la vendita con successo della struttura di Plano, TX, per 9,5 milioni di dollari, una riduzione del debito superiore a 8 milioni di dollari e una raccolta di capitale azionario di 1,5 milioni di dollari tramite Impact BioMedical. Il flusso di cassa operativo è migliorato, con il netto utilizzo di cassa nelle operazioni che è diminuito da 2,15 milioni di dollari nel primo trimestre 2024 a 1,64 milioni nel primo trimestre 2025.
DSS reportó sólidos resultados financieros en el primer trimestre de 2025, demostrando un progreso significativo en su estrategia de reposicionamiento financiero. La empresa logró un crecimiento de ingresos interanual del 28%, impulsado por un aumento del 30% en las ventas de productos impresos y un impresionante crecimiento del 78,5% en los ingresos por alquiler, que pasaron de 400,000 a 714,000 dólares. Los aspectos financieros clave incluyen la exitosa venta de su instalación en Plano, TX, por 9.5 millones de dólares, una reducción de deuda superior a 8 millones de dólares y una recaudación de capital de 1.5 millones de dólares a través de Impact BioMedical. El flujo de caja operativo mejoró, con una disminución del efectivo neto utilizado en operaciones de 2.15 millones de dólares en el primer trimestre de 2024 a 1.64 millones en el primer trimestre de 2025.
DSS는 2025년 1분기 강력한 재무 실적을 보고하며 재무 재조정 전략에서 상당한 진전을 보였습니다. 회사는 전년 대비 28% 매출 성장을 달성했으며, 이는 인쇄 제품 판매가 30% 증가하고 임대 수익이 40만 달러에서 71만 4천 달러로 78.5% 크게 성장한 데 힘입은 결과입니다. 주요 재무 하이라이트로는 텍사스 플라노에 위치한 시설을 950만 달러에 성공적으로 매각한 점, 800만 달러 이상의 부채 감축, Impact BioMedical을 통한 150만 달러의 자본 증자가 포함됩니다. 영업 현금 흐름도 개선되어 2024년 1분기 215만 달러였던 영업 현금 순사용액이 2025년 1분기에는 164만 달러로 감소했습니다.
DSS a annoncé de solides résultats financiers pour le premier trimestre 2025, démontrant des progrès significatifs dans sa stratégie de repositionnement financier. L'entreprise a réalisé une croissance du chiffre d'affaires de 28 % en glissement annuel, portée par une augmentation de 30 % des ventes de produits imprimés et une croissance impressionnante de 78,5 % des revenus locatifs, passant de 400 000 à 714 000 dollars. Les points financiers clés incluent la vente réussie de son site de Plano, TX, pour 9,5 millions de dollars, une réduction de la dette de plus de 8 millions de dollars et une levée de fonds en capital de 1,5 million de dollars via Impact BioMedical. Le flux de trésorerie opérationnel s'est amélioré, avec une diminution des liquidités nettes utilisées dans les opérations, passant de 2,15 millions de dollars au premier trimestre 2024 à 1,64 million au premier trimestre 2025.
DSS meldete starke Finanzergebnisse für das erste Quartal 2025 und zeigte damit erhebliche Fortschritte in seiner finanziellen Neuausrichtungsstrategie. Das Unternehmen erzielte ein Umsatzwachstum von 28 % im Jahresvergleich, angetrieben durch einen 30%igen Anstieg der Verkäufe gedruckter Produkte und ein beeindruckendes Wachstum der Mieteinnahmen um 78,5 %, von 400.000 auf 714.000 US-Dollar. Zu den wichtigsten finanziellen Highlights zählen der erfolgreiche Verkauf der Anlage in Plano, TX, für 9,5 Millionen US-Dollar, eine Schuldenreduzierung von über 8 Millionen US-Dollar sowie eine Kapitalerhöhung in Höhe von 1,5 Millionen US-Dollar durch Impact BioMedical. Der operative Cashflow verbesserte sich, wobei der Netto-Cashflow aus der Geschäftstätigkeit von 2,15 Millionen US-Dollar im ersten Quartal 2024 auf 1,64 Millionen US-Dollar im ersten Quartal 2025 sank.
- 28% year-over-year revenue growth with 30% increase in printed product sales
- 78.5% growth in rental income from real estate segment ($400,000 to $714,000)
- Successfully sold Plano facility for $9.5 million
- Reduced total debt by over $8 million
- Raised $1.5 million in new equity capital through Impact BioMedical
- Improved operating cash flow with reduced cash burn ($2.15M to $1.64M)
- Still operating at a cash loss with $1.64 million used in operations
Insights
DSS shows financial turnaround with 28% revenue growth, significant debt reduction, and improved cash flow positioning the company for accelerated growth.
The Q1 2025 results demonstrate a meaningful financial turnaround for DSS, with 28% year-over-year revenue growth reaching new momentum. This growth is well-diversified, coming from both the core printed products business (up 30%) and an impressive 78.5% increase in real estate rental income (from
The company's strategic asset monetization is particularly noteworthy. By selling its Plano facility for
Cash flow trends show encouraging progress with net cash used in operations improving by
The strategic repositioning under CEO Jason Grady appears to be gaining traction, with the company pivoting from financial restructuring toward growth initiatives. The diversified business model across packaging, real estate, and biomedical sectors provides multiple avenues for expansion. With the balance sheet cleanup largely addressed, management can now focus on higher-margin opportunities and potential M&A activity in the second half of 2025.
NEW YORK, May 22, 2025 (GLOBE NEWSWIRE) -- DSS, Inc. (NYSE American: DSS), a multinational company operating across diverse industries including packaging, real estate, and biomedical innovation, today announced financial results for the first quarter of 2025, highlighting meaningful progress in its financial repositioning and a strong foundation for corporate execution in the coming quarters.
In a quarter focused on streamlining operations and financial discipline, DSS delivered significant improvements in key financial metrics:
28% Year-Over-Year Revenue Growth: Total revenues rose sharply, fueled by a30% increase in printed product sales and a nearly doubling of rental income from the company’s real estate segment, which grew from$400,000 t o$714,000.
- Strategic Asset Monetization: The Company completed the sale of its Plano, TX facility, for
$9.5 million , contributing to$12.88 million in cash from investing activities during the quarter.
- Debt Reduction and Capital Discipline: DSS used proceeds from asset sales and investments to pay down over
$8 million in total debt, reflecting a clear commitment to balance sheet optimization.
- Strengthening Shareholder Equity: Through its partner company Impact BioMedical, DSS raised
$1.5 million in new equity capital during Q1.
- Improved Operating Cash Flow: Net cash used in operations improved from
$2.15 million in Q1 2024 to$1.64 million in Q1 2025, underscoring early operational efficiencies.
“These results show clear, measurable progress in the financial realignment strategy we launched earlier this year,” said Jason Grady, CEO of DSS, Inc. “In my January letter to shareholders, I outlined the urgent need to cut inefficiencies, strengthen our balance sheet, and lay the groundwork for sustained growth. This quarter proves that work is paying off. As we continue to streamline operations, we’re now turning our attention toward execution in our core verticals and identifying smart, accretive opportunities that will drive long-term value. The foundation is in place and now we’re building on it.”
The Company plans to continue to showcase measurable results from initiatives in development, operations, and M&A activity as the year progresses. With a renewed focus on high-potential business units and capital allocation, DSS is positioning itself for a dynamic second half of 2025 and beyond.
To read the 2025 CEO shareholder letter, visit: investors.dssworld.com
Forward-looking Statements:
The foregoing material may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. Except as required by applicable law, including the security laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
About DSS, Inc.:
DSS, Inc. (NYSE American: DSS) is a multinational company operating businesses across multiple high-growth sectors. DSS focuses on creating, acquiring, and investing in innovative companies that drive sustainable value for its shareholders.
For investor and media inquiries or additional information, please contact:
DSS, Inc. Investor Relations
Email: IR@dssworld.com
Phone: +1 (585) 565-2422
FAQ
What was DSS's revenue growth in Q1 2025?
How much debt did DSS pay down in Q1 2025?
How much did DSS sell its Plano, TX facility for?
What was DSS's operating cash flow improvement in Q1 2025?
How much equity capital did DSS raise through Impact BioMedical in Q1 2025?
